ADRENERGIC BLOCKADE, GLUCOSE METABOLISM AND RISK FOR DIABETES

肾上腺素能阻断、葡萄糖代谢和糖尿病风险

• 批准号: 5215587
• 负责人: RICHARD SAMUEL SURWIT
• 金额: --
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/5215587
• 关键词: alpha antiadrenergic agent; clinical research; disease /disorder proneness /risk; female; gestational diabetes mellitus; glucose metabolism; glucose tolerance; glucose tolerance test; hormone regulation /control mechanism; human subject; insulin sensitivity /resistance; prediabetic state

There is evidence of altered pancreatic adrenergic activity in humans with non-insulin dependent diabetes mellitus (NIDDM). We have hypothesized that altered adrenergic control of glucose metabolism is related to the pathophysiology of NIDDM, and may be evident in persons currently euglycemic, but at high risk for developing NIDDM in the future. This three year study will be conducted on the Clinical Research Unit at Duke University Medical Center. Forty women with a documented history of gestational diabetes will be recruited. Forty parous control women, matched by age and body mass index, will also be recruited. Controls will have documented normal glucose challenge in pregnancy, and no primary relative with diabetes (parent, child, sibling). Subjects will undergo oral and intravenous glucose tolerance testing after therapy with phenoxybenzamine (alpha adrenergic blocking agent) and again after placebo in a counterbalanced, single-blinded paradigm. Glucose stimulated insulin release, first phase insulin release and glucose tolerance will be assessed using a 2 X 2 analysis of variance with 2 groups and 2 conditions (drug/placebo).

有证据表明人类胰腺肾上腺素能活性改变 非胰岛素依赖性糖尿病（NIDDM）。 我们有 假设改变葡萄糖代谢的肾上腺素能控制是 与NIDDM的病理生理学有关，可能在人中很明显 目前的尤格血糖，但在开发NIDDM的高风险 未来。 这项三年的研究将在临床研究部门进行 杜克大学医学中心。 有记录有史以来历史的四十名妇女 妊娠糖尿病将被招募。 四十个帕斯控制妇女， 按年龄和体重指数匹配，也将被招募。 控件 将记录怀孕中正常的葡萄糖挑战，没有 糖尿病的初级亲戚（父母，孩子，兄弟姐妹）。 受试者会 治疗后接受口服和静脉注射葡萄糖耐量测试 苯氧苯甲胺（α肾上腺素能阻断剂），然后在 安慰剂以平衡的单叶范式。 葡萄糖 刺激的胰岛素释放，第一相胰岛素释放和葡萄糖 将使用2 x 2的方差分析（2）评估公差 组和2个条件（药物/安慰剂）。